KREBS BIOCHEMICALS & IND (KREBSBIO) financials

KREBS BIOCHEMICALS & IND (KREBSBIO) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.

Market Cap: ₹130Cr.
Current Price: ₹60.2
ROE: %
ROCE: -15.4%
Book Value: ₹-75.5
Dividend Yield: 0.00%
52W High / Low: ₹76.8/38.3

In Jun 2026, KREBS BIOCHEMICALS & IND (KREBSBIO) reported sales ₹6.98 Cr and net profit ₹-2.48 Cr.

Annual TTM: sales ₹25 Cr, net profit ₹-14 Cr.

Shareholding: Promoters 72.74% (Sep 2026), FIIs 0.50% (Sep 2026), Public 26.75% (Sep 2026), No. of Shareholders 8,533% (Sep 2026).

KREBSBIO quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	12.86	11.47	6.10	5.48	4.17	7.27	6.81	6.98
Expenses	15.58	16.18	11.51	7.57	6.97	6.97	7.67	6.16
Operating Profit	-2.72	-4.71	-5.41	-2.09	-2.80	0.30	-0.86	0.82
OPM %	-21.15%	-41.06%	-88.69%	-38.14%	-67.15%	4.13%	-12.63%	11.75%
Other Income	0.09	0.25	0.34	0.01	0.01	0.00	2.00	0.16
Interest	1.42	1.56	1.61	1.65	1.73	1.79	1.91	1.88
Depreciation	1.71	1.72	1.57	1.60	1.62	1.63	1.57	1.59
Profit before tax	-5.76	-7.74	-8.25	-5.33	-6.14	-3.12	-2.34	-2.49
Tax %	0.00%	0.00%	0.24%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	-5.76	-7.74	-8.27	-5.32	-6.14	-3.13	-2.34	-2.48
EPS in Rs	-2.67	-3.59	-3.84	-2.47	-2.85	-1.45	-1.09	-1.15
Raw PDF	—	—	—	—	—	—	—	—

KREBSBIO profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	33	54	60	52	50	43	24	25
Expenses	52	71	94	68	59	58	29	28
Operating Profit	-19	-18	-34	-16	-9	-15	-5	-3
OPM %	-56%	-33%	-57%	-30%	-17%	-35%	-23%	-10%
Other Income	0	1	1	1	0	1	2	2
Interest	6	6	5	3	5	6	7	7
Depreciation	5	5	6	7	7	7	6	6
Profit before tax	-29	-28	-45	-25	-20	-27	-17	-14
Tax %	0%	0%	0%	0%	0%	0%	0%	—
Net Profit	-29	-28	-45	-25	-20	-27	-17	-14
EPS in Rs	-16.04	-14.45	-20.65	-11.45	-9.15	-12.50	-7.85	-6.54
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	—

KREBSBIO balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	17	18	20	22	22	22	22	22
Reserves	-31	-43	-62	-97	-121	-141	-168	-184
Borrowings	53	66	111	143	183	194	212	225
Other Liabilities	103	93	91	122	91	104	103	101
Total Liabilities	142	134	159	190	175	178	169	163
Fixed Assets	101	105	118	139	147	150	146	142
CWIP	3	4	12	8	4	2	3	2
Investments	0	0	0	0	0	0	0	0
Other Assets	38	24	29	43	24	26	20	20
Total Assets	142	134	159	190	175	178	169	163

KREBSBIO cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	4	-36	-15	-17	-25	2	-8	-2
Cash from Investing Activity	-4	-10	-23	-23	-13	-8	-5	-4
Cash from Financing Activity	17	29	38	40	37	6	13	6
Net Cash Flow	17	-17	1	-1	-0	0	0	-0
Free Cash Flow	-1	-45	-40	-41	-36	-5	-11	-5
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	-40%	191%	83%	51%	157%	-27%	52%	35%

KREBSBIO shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%
FIIs	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%
Public	26.76%	26.75%	26.76%	26.76%	26.76%	26.77%	26.76%	26.75%
No. of Shareholders	9,091	8,798	9,118	8,912	8,710	8,553	8,521	8,533

KREBSBIO key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	22	2	2	5	4	14	0	0
Inventory Days	142	345	234	230	170	543	396	—
Days Payable	339	521	292	340	217	1,051	1,192	—
Cash Conversion Cycle	-175	-174	-57	-106	-44	-494	-795	0
Working Capital Days	-315	-267	-187	-261	-232	-322	-787	-1,593
ROCE %	-36%	-57%	-40%	-57%	-29%	-19%	-30%	-15%

KREBSBIOUpdated 18 Oct 2026, 11:07

Krebs Biochemicals & Ind

KREBSBIOUpdated 18 Oct 2026, 11:07

Market Cap

₹130Cr.

Current Price

₹60.2

High / Low

₹76.8/38.3

ROE%

ROCE-15.4%

Book Value₹-75.5

Face Value₹10.0

Dividend Yield0.00%

About

Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	10.58	1.1	13.2	0.04	1.65	-5.33	0	-5.33	-2.47
Sep 2023	14.89	1.13	15.79	0.17	1.71	-3.57	0	-3.57	-1.66
Dec 2023	12.98	1.19	15.07	0.03	1.73	-4.98	0	-4.98	-2.31
Mar 2024	11.97	1.27	15.09	0.21	1.67	-5.85	0	-5.85	-2.71
Jun 2024	12.89	1.32	15.08	0.03	1.69	-5.17	0	-5.17	-2.4
Sep 2024	12.86	1.42	15.58	0.09	1.71	-5.76	0	-5.76	-2.67
Dec 2024	11.47	1.56	16.18	0.25	1.72	-7.74	0	-7.74	-3.59
Mar 2025	6.1	1.61	11.51	0.34	1.57	-8.25	0.24	-8.27	-3.84
Jun 2025	5.48	1.65	7.57	0.01	1.6	-5.33	0	-5.32	-2.47
Sep 2025	4.17	1.73	6.97	0.01	1.62	-6.14	0	-6.14	-2.85
Dec 2025	7.27	1.79	6.97	0	1.63	-3.12	0	-3.13	-1.45
Mar 2026	6.81	1.91	7.67	2	1.57	-2.34	0	-2.34	-1.09
Jun 2026	6.98	1.88	6.16	0.16	1.59	-2.49	0	-2.48	-1.15

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015 6m	0	4	5	3	2	-8	0	-8	-6.82
Mar 2016	1	1	14	1	4	-16	0	-16	-10.33
Mar 2017	3	3	11	0	4	-16	0	-16	-9.67
Mar 2018	34	5	41	-1	4	-18	0	-18	-10.73
Mar 2019	48	6	58	0	4	-20	0	-20	-12.03
Mar 2020	33	6	52	0	5	-29	0	-29	-16.04
Mar 2021	54	6	71	1	5	-28	0	-28	-14.45
Mar 2022	60	5	94	1	6	-45	0	-45	-20.65
Mar 2023	52	3	68	1	7	-25	0	-25	-11.45
Mar 2024	50	5	59	0	7	-20	0	-20	-9.15
Mar 2025	43	6	58	1	7	-27	0	-27	-12.5
Mar 2026	24	7	29	2	6	-17	0	-17	-7.85
TTM	25	7	28	2	6	-14	—	-14	-6.54

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	72.74%
FIIs	0.5%
Public	26.75%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	Public
Dec 2023	72.74%	0.5%	26.77%
Mar 2024	72.74%	0.5%	26.75%
Jun 2024	72.74%	0.5%	26.75%
Sep 2024	72.74%	0.5%	26.76%
Dec 2024	72.74%	0.5%	26.76%
Mar 2025	72.74%	0.5%	26.75%
Jun 2025	72.74%	0.5%	26.76%
Sep 2025	72.74%	0.5%	26.76%
Dec 2025	72.74%	0.5%	26.76%
Mar 2026	72.74%	0.5%	26.77%
Jun 2026	72.74%	0.5%	26.76%
Sep 2026	72.74%	0.5%	26.75%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Other Assets	Total Assets
Mar 2015	10	9	61	29	108	58	0	50	108
Mar 2016	13	0	31	73	116	93	11	13	116
Mar 2017	14	-12	48	73	122	102	4	16	122
Mar 2018	14	-32	56	87	126	101	4	21	126
Mar 2019	17	-31	53	103	142	101	3	38	142
Mar 2020	18	-43	66	93	134	105	4	24	134
Mar 2021	20	-62	111	91	159	118	12	29	159
Mar 2022	22	-97	143	122	190	139	8	43	190
Mar 2023	22	-121	183	91	175	147	4	24	175
Mar 2024	22	-141	194	104	178	150	2	26	178
Mar 2025	22	-168	212	103	169	146	3	20	169
Mar 2026	22	-184	225	101	163	142	2	20	163

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-45	-3	54	6
Mar 2016	-15	-4	13	-6
Mar 2017	-11	-5	16	0
Mar 2018	-6	-3	9	0
Mar 2019	4	-4	17	17
Mar 2020	-36	-10	29	-17
Mar 2021	-15	-23	38	1
Mar 2022	-17	-23	40	-1
Mar 2023	-25	-13	37	0
Mar 2024	2	-8	6	0
Mar 2025	-8	-5	13	0
Mar 2026	-2	-4	6	0

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	—	10	180	3	22	2	2	5	4	14	0	0
Inventory Days	—	14,704	2,162	337	142	345	234	230	170	543	396	—
Days Payable	—	32,250	4,360	510	339	521	292	340	217	1,051	1,192	—
Cash Conversion Cycle	—	-17,536	-2,018	-170	-175	-174	-57	-106	-44	-494	-795	0
Working Capital Days	—	-6,532	-2,132	-275	-315	-267	-187	-261	-232	-322	-787	-1,593
ROCE %	—	-26%	-26%	-26%	-36%	-57%	-40%	-57%	-29%	-19%	-30%	-15%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of KREBS BIOCHEMICALS & IND (KREBSBIO)?

The reported market capitalisation for KREBS BIOCHEMICALS & IND (KREBSBIO) is ₹130Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of KREBSBIO?

The current price shown for KREBS BIOCHEMICALS & IND (KREBSBIO) on Fincrux is ₹60.2 with a 52-week high/low of ₹76.8/38.3.

What were KREBSBIO latest quarterly results?

For Jun 2026, KREBS BIOCHEMICALS & IND (KREBSBIO) reported sales ₹6.98 Cr and net profit ₹-2.48 Cr (figures in ₹ crore unless noted).

What are KREBSBIO annual sales and net profit?

For TTM, KREBS BIOCHEMICALS & IND (KREBSBIO) shows sales of ₹25 Cr and net profit of ₹-14 Cr on the Fincrux profit & loss statement.

Who owns KREBS BIOCHEMICALS & IND (KREBSBIO)?

Latest shareholding for KREBS BIOCHEMICALS & IND (KREBSBIO) on Fincrux: Promoters 72.74% (Sep 2026), FIIs 0.50% (Sep 2026), Public 26.75% (Sep 2026), No. of Shareholders 8,533% (Sep 2026).

Where can I find KREBS BIOCHEMICALS & IND (KREBSBIO) financials?

KREBS BIOCHEMICALS & IND (KREBSBIO) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show KREBSBIO balance sheet and cash flow?

Yes. The KREBS BIOCHEMICALS & IND (KREBSBIO) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 11:07